Satellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants. The company reported results from four adults with Duchenne muscular dystrophy, or DMD, ages 21 to 28, who had previously completed [...]
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
